SE510650C2 - Ny förening - Google Patents
Ny föreningInfo
- Publication number
- SE510650C2 SE510650C2 SE9702065A SE9702065A SE510650C2 SE 510650 C2 SE510650 C2 SE 510650C2 SE 9702065 A SE9702065 A SE 9702065A SE 9702065 A SE9702065 A SE 9702065A SE 510650 C2 SE510650 C2 SE 510650C2
- Authority
- SE
- Sweden
- Prior art keywords
- omeprazole
- magnesium salt
- salt
- magnesium
- trihydrate
- Prior art date
Links
- 229960000381 omeprazole Drugs 0.000 claims abstract description 57
- 159000000003 magnesium salts Chemical class 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 43
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 210000004211 gastric acid Anatomy 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000011777 magnesium Substances 0.000 claims description 5
- 229910052749 magnesium Inorganic materials 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 3
- XURCIPRUUASYLR-UHFFFAOYSA-N Omeprazole sulfide Chemical compound N=1C2=CC(OC)=CC=C2NC=1SCC1=NC=C(C)C(OC)=C1C XURCIPRUUASYLR-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- -1 4-methoxy-3,5-dimethyl-2-pyridinyl Chemical group 0.000 abstract description 6
- 239000000543 intermediate Substances 0.000 abstract description 3
- 150000004684 trihydrates Chemical class 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 description 22
- 239000000203 mixture Substances 0.000 description 18
- 239000013078 crystal Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010019375 Helicobacter infections Diseases 0.000 description 2
- 208000028861 Helicobacter pylori infectious disease Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- SUBDBMMJDZJVOS-XMMPIXPASA-N (R)-omeprazole Chemical class C([S@@](=O)C=1NC2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-XMMPIXPASA-N 0.000 description 1
- FRIBMENBGGCKPD-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enal Chemical compound COC1=CC=CC(C=CC=O)=C1OC FRIBMENBGGCKPD-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 244000304337 Cuminum cyminum Species 0.000 description 1
- 235000007129 Cuminum cyminum Nutrition 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
- 239000000159 acid neutralizing agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 206010013864 duodenitis Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- TZNULHNPXDZANP-UHFFFAOYSA-N magnesium;methanol Chemical compound [Mg].OC TZNULHNPXDZANP-UHFFFAOYSA-N 0.000 description 1
- CRGZYKWWYNQGEC-UHFFFAOYSA-N magnesium;methanolate Chemical compound [Mg+2].[O-]C.[O-]C CRGZYKWWYNQGEC-UHFFFAOYSA-N 0.000 description 1
- YYINWHOQKIUBNL-UHFFFAOYSA-N magnesium;trihydrate Chemical compound O.O.O.[Mg] YYINWHOQKIUBNL-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- BKBMACKZOSMMGT-UHFFFAOYSA-N methanol;toluene Chemical compound OC.CC1=CC=CC=C1 BKBMACKZOSMMGT-UHFFFAOYSA-N 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940071462 oralone Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002325 prokinetic agent Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Glass Compositions (AREA)
Priority Applications (73)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9702065A SE510650C2 (sv) | 1997-05-30 | 1997-05-30 | Ny förening |
| US09/077,719 US6369085B1 (en) | 1997-05-30 | 1998-05-05 | Form of S-omeprazole |
| HR980263A HRP980263B1 (en) | 1997-05-30 | 1998-05-15 | Novel form of s-omeprazole |
| DZ980105A DZ2495A1 (fr) | 1997-05-30 | 1998-05-18 | Formule nouvelle de l'oméprazole-s. |
| ZA984179A ZA984179B (en) | 1997-05-30 | 1998-05-18 | Novel form of s-omeprazole |
| TW087107675A TW538040B (en) | 1997-05-30 | 1998-05-18 | Novel form of S-omeprazole |
| ARP980102299A AR012717A1 (es) | 1997-05-30 | 1998-05-18 | Trihidrato de la sal de magnesio de s-omeprazol, proceso para su preparacion, composicion farmaceutica, y uso de dicho trihidrato para la fabricacion de medicamentos. |
| MA25085A MA26500A1 (fr) | 1997-05-30 | 1998-05-21 | Forme nouvelle de s-omerprazole |
| HU0001849A HU225987B1 (en) | 1997-05-30 | 1998-05-25 | Novel form of s-omeprazole |
| HK00105176.5A HK1025962B (en) | 1997-05-30 | 1998-05-25 | Novel form of s-omeprazole |
| MEP-2008-249A ME00198B (me) | 1997-05-30 | 1998-05-25 | Novi oblik s-omeprazola |
| UA99116288A UA60334C2 (uk) | 1997-05-30 | 1998-05-25 | Тригідрат магнієвої солі (s)-омепразолу, спосіб отримання тригідрату магнієвої солі (s)-омепразолу (варіанти), спосіб отримання калієвої солі (s)-омепразолу, калієва сіль (s)-омепразолу, фармацевтична композиція та спосіб лікування стану, пов'язаного з порушенням шлункової секреції |
| PT02019642T PT1273581E (pt) | 1997-05-30 | 1998-05-25 | Novo processo para a preparacao do sal de magnesio de s-omeprazole tri-hidratado |
| SK1625-99A SK284837B6 (sk) | 1997-05-30 | 1998-05-25 | Trihydrát horečnatej soli S-omeprazolu, spôsob jeho prípravy, farmaceutická kompozícia s jeho obsahom a jeho použitie |
| CZ20041090A CZ297585B6 (cs) | 1997-05-30 | 1998-05-25 | Nový způsob přípravy trihydrátu hořečnatésoli S-omeprazolu |
| ES02019642T ES2236407T3 (es) | 1997-05-30 | 1998-05-25 | Nuevo procedimiento para la preparacion del trihidrato de la sal magnesica de s-omeprazol. |
| AT98926005T ATE239011T1 (de) | 1997-05-30 | 1998-05-25 | Neuartige form von s-omeprazol |
| BR9809509-9A BR9809509A (pt) | 1997-05-30 | 1998-05-25 | Composto, processo para preparação e uso do sal de magnésio de s-omeprazol triidratado, composição farmacêutica, e, processo para tratamento de uma condição relacionada com acidez gástrica |
| EP02019642A EP1273581B1 (en) | 1997-05-30 | 1998-05-25 | New process for the preparation of the trihydrate of the magnesium salt of S-omeprazole |
| PCT/SE1998/000974 WO1998054171A1 (en) | 1997-05-30 | 1998-05-25 | Novel form of s-omeprazole |
| CNB98805521XA CN1161351C (zh) | 1997-05-30 | 1998-05-25 | 新型s-奥美拉唑 |
| ES98926005.4T ES2195345T7 (es) | 1997-05-30 | 1998-05-25 | Nueva forma de S-omeprazol |
| MEP-249/08A MEP24908A (en) | 1997-05-30 | 1998-05-25 | Novel form of s-omeprazole |
| JP50057899A JP4002303B2 (ja) | 1997-05-30 | 1998-05-25 | Ｓ−オメプラゾールの新規な形態 |
| NZ500991A NZ500991A (en) | 1997-05-30 | 1998-05-25 | Magnesium salt of S-omeprazole |
| EEP199900550A EE03875B1 (et) | 1997-05-30 | 1998-05-25 | S-omeprasooli uus vorm |
| DE69829511T DE69829511T2 (de) | 1997-05-30 | 1998-05-25 | Neuer Prozess zur Herstellung von S-Omeprazol-Magnesiumsalz-Trihydrat |
| SI9830761T SI1273581T1 (forum.php) | 1997-05-30 | 1998-05-25 | |
| KR10-2005-7006896A KR100527804B1 (ko) | 1997-05-30 | 1998-05-25 | Ｓ-오메프라졸의 칼륨염 |
| AU77935/98A AU722839B2 (en) | 1997-05-30 | 1998-05-25 | Novel form of S-omeprazole |
| SK76-2005A SK285137B6 (sk) | 1997-05-30 | 1998-05-25 | Spôsob prípravy trihydrátu horečnatej soli S-omeprazolu, draselná soľ S-omeprazolu a spôsob jej prípravy |
| PL98337180A PL193546B1 (pl) | 1997-05-30 | 1998-05-25 | Trihydrat soli magnezowej S-omeprazolu, sposób wytwarzania trihydratu soli magnezowej S-omeprazolu,sól potasowa S-omeprazolu, sposób wytwarzania soli potasowej S-omeprazolu, środek farmaceutyczny i zastosowanie trihydratu soli magnezowej S-omeprazolu |
| CA002521391A CA2521391C (en) | 1997-05-30 | 1998-05-25 | Potassium salt of s-omeprazole as intermediate in the preparation of the magnesium salt of s-omeprazole trihydrate |
| YUP-609/99A RS50005B (sr) | 1997-05-30 | 1998-05-25 | Novi oblik s-omeprazola |
| RSP-2007/0459A RS50067B (sr) | 1997-05-30 | 1998-05-25 | Novi postupak dobijanja trihidrata soli magnezijum-s- omeprazola |
| PT98926005T PT984957E (pt) | 1997-05-30 | 1998-05-25 | Novas formas de s-omeprazole |
| IDW991449A ID29306A (id) | 1997-05-30 | 1998-05-25 | Bentuk baru s-omeprazola |
| IL13294798A IL132947A0 (en) | 1997-05-30 | 1998-05-25 | Novel form of s-omeprazole |
| CA002290963A CA2290963C (en) | 1997-05-30 | 1998-05-25 | S-omeprazole magnesium trihydrate |
| RU99128072/04A RU2184115C2 (ru) | 1997-05-30 | 1998-05-25 | Тригидрат магниевой соли s-омепразола, способы его получения, промежуточный продукт для его получения, содержащая его фармацевтическая композиция и способ лечения |
| MEP-180/08A MEP18008A (en) | 1997-05-30 | 1998-05-25 | New process for the preparation of tryhidrate of magnesium salt of s-omeprasole |
| KR1019997011106A KR100540720B1 (ko) | 1997-05-30 | 1998-05-25 | 신규형의 ｓ-오메프라졸 |
| DK02019642T DK1273581T3 (da) | 1997-05-30 | 1998-05-25 | Ny fremgangsmåde til fremstilling af trihydratet af magnesiumsaltet af S-omeprazol |
| SI9830424T SI0984957T1 (en) | 1997-05-30 | 1998-05-25 | Novel form of s-omeprazole |
| EP98926005.4A EP0984957B3 (en) | 1997-05-30 | 1998-05-25 | Novel form of s-omeprazole |
| DE69814069.9T DE69814069T3 (de) | 1997-05-30 | 1998-05-25 | Neuartige form von s-omeprazol |
| AT02019642T ATE291574T1 (de) | 1997-05-30 | 1998-05-25 | Neuer prozess zur herstellung von s-omeprazol- magnesiumsalz-trihydrat |
| TR1999/02934T TR199902934T2 (xx) | 1997-05-30 | 1998-05-25 | S-Omeprazol�n yeni yap�s�. |
| DK98926005T DK0984957T3 (da) | 1997-05-30 | 1998-05-25 | Hidtil ukendt form af S-omeprazol |
| EG58098A EG24291A (en) | 1997-05-30 | 1998-05-27 | Novel form of s-omeprazole |
| MYPI20032997A MY127793A (en) | 1997-05-30 | 1998-05-29 | Novel form of s-omeprazole. |
| TNTNSN98074A TNSN98074A1 (fr) | 1997-05-30 | 1998-05-29 | Forme nouvelle de l'omeprazoles |
| MYPI98002399A MY120745A (en) | 1997-05-30 | 1998-05-29 | Novel form of s-omeprazole |
| SA5260296A SA05260296B1 (ar) | 1997-05-30 | 1998-07-12 | عملية جديدة لتحضير تراي هيدرات ملح الماغنسيوم trihydrate of the magnesium salt من أوميبرازول S-omeprazole |
| SA98190280A SA98190280B1 (ar) | 1997-05-30 | 1998-07-12 | صيغة جديدة لـ -s إس أومبرازول s-omeprazole |
| IS5272A IS2142B (is) | 1997-05-30 | 1999-11-25 | Nýtt form S-ómeprasóls |
| NO19995852A NO317518B1 (no) | 1997-05-30 | 1999-11-29 | Ny form av S-omeprazol, farmasoytisk preparat som inneholder denne, fremgangmsate for dens fremstilling, anvendelse derav samt mellomprodukt og dets fremstilling |
| HK03103300.6A HK1051681B (en) | 1997-05-30 | 2000-08-17 | New process for the preparation of the trihydrate of the magnesium salt of s-omeprazole |
| US10/076,711 US6677455B2 (en) | 1997-05-30 | 2002-02-14 | Potassium salt of S-omeprazole |
| US10/113,245 US6747155B2 (en) | 1997-05-30 | 2002-04-01 | Process |
| US10/672,936 US7411070B2 (en) | 1997-05-30 | 2003-09-25 | Form of S-omeprazole |
| IS8368A IS2774B (is) | 1997-05-30 | 2006-03-22 | Ný aðferð til að framleiða tríhýdrat magnesíumsalt S-ómeprasóls |
| ARP070100714A AR059589A2 (es) | 1997-05-30 | 2007-02-20 | Proceso para la preparacion de sal de magnesio de trihidrato de s-omeprazol, sal de potasio de s-omeprazol intermediaria y proceso para prepararla |
| JP2007068061A JP2007161734A (ja) | 1997-05-30 | 2007-03-16 | Ｓ−オメプラゾールの新規な形態 |
| US11/853,323 US7745466B2 (en) | 1997-05-30 | 2007-09-11 | Form of S-omeprazole |
| US12/784,881 US8076361B2 (en) | 1997-05-30 | 2010-05-21 | Form of S-omeprazole |
| NO2011010C NO2011010I1 (no) | 1997-05-30 | 2011-06-07 | Naproksen- og esomeprazoltabletter med modifisert frisetting |
| LU91871C LU91871I2 (fr) | 1997-05-30 | 2011-09-19 | Une combinaison de produit comprenant du naproxèneet de l'ésoméprazole (magnésium trihydrate) |
| US13/298,373 US8466175B2 (en) | 1997-05-30 | 2011-11-17 | Form of S-omeprazole |
| DE201212000017 DE122012000017I1 (de) | 1997-05-30 | 2012-03-26 | Neuartige form von s-omeprazol. |
| NO2012011C NO2012011I1 (no) | 1997-05-30 | 2012-06-05 | Aspirin og esomeprazol magnesiumtrihydrat |
| LU92017C LU92017I2 (fr) | 1997-05-30 | 2012-06-06 | Une combinaison de produit comprenant de l'aspirine et de l'ésoméprazole (magnésium trihydrate). |
| CY2012029C CY2012029I1 (el) | 1997-05-30 | 2012-11-05 | Νεα μορφη της s-ομεπραζολης |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9702065A SE510650C2 (sv) | 1997-05-30 | 1997-05-30 | Ny förening |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE9702065D0 SE9702065D0 (sv) | 1997-05-30 |
| SE9702065L SE9702065L (sv) | 1998-12-01 |
| SE510650C2 true SE510650C2 (sv) | 1999-06-14 |
Family
ID=20407186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9702065A SE510650C2 (sv) | 1997-05-30 | 1997-05-30 | Ny förening |
Country Status (43)
Families Citing this family (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| US6875872B1 (en) * | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
| US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| DE69737413T2 (de) | 1996-01-04 | 2007-10-31 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Bakterioferritin aus helicobacter pylori |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| SE510650C2 (sv) | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
| SE9900274D0 (sv) * | 1999-01-28 | 1999-01-28 | Astra Ab | New compound |
| US6369087B1 (en) * | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| CA2474246C (en) * | 2002-03-05 | 2010-06-29 | Astrazeneca Ab | Alkylammonium salts of omeprazole and esomeprazole |
| AU2003262375A1 (en) * | 2002-04-22 | 2003-11-03 | Sun Pharmaceutical Industries Limited | Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts |
| CN100378093C (zh) * | 2002-06-27 | 2008-04-02 | 雷迪实验室有限公司 | 一种制备包括无定形艾美拉唑及其盐在内的光学纯或光学浓缩的亚砜化合物的方法 |
| EP1515963B1 (en) | 2002-06-27 | 2007-02-14 | Dr. Reddy's Laboratories Ltd. | A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof |
| TW200410955A (en) | 2002-07-29 | 2004-07-01 | Altana Pharma Ag | Novel salt of (S)-PANTOPRAZOLE |
| CA2501424A1 (en) * | 2002-08-30 | 2004-03-11 | Dr. Reddy's Laboratories Limited | Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof |
| EP2596791B1 (en) * | 2002-10-16 | 2015-04-01 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
| US20040235903A1 (en) * | 2002-10-22 | 2004-11-25 | Khanna Mahavir Singh | Amorphous form of esomeprazole salts |
| US20040242642A1 (en) * | 2002-11-18 | 2004-12-02 | Dr. Reddy's Laboratories Limited | Crystalline esomeprazole compounds and process for the preparation thereof |
| EP1583507A2 (en) * | 2003-01-07 | 2005-10-12 | Ranbaxy Laboratories Limited | Magnesium salt of imidazole derivative |
| WO2004089935A1 (en) * | 2003-04-10 | 2004-10-21 | Hetero Drugs Limitd | Novel crystalline forms of s-omeprazole magnesium |
| EP1633736A1 (en) | 2003-05-05 | 2006-03-15 | Ranbaxy Laboratories Limited | Barium salt of benzimidazole derivative |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| JP2006528158A (ja) * | 2003-07-23 | 2006-12-14 | アルタナ ファルマ アクチエンゲゼルシャフト | プロトンポンプ阻害剤のアルカリ塩 |
| CN100457104C (zh) * | 2003-07-23 | 2009-02-04 | 尼科梅德有限责任公司 | 质子泵抑制剂的碱性盐 |
| SE0302382D0 (sv) | 2003-09-04 | 2003-09-04 | Astrazeneca Ab | New salts II |
| SE0302381D0 (sv) | 2003-09-04 | 2003-09-04 | Astrazeneca Ab | New salts I |
| US20050075371A1 (en) * | 2003-10-03 | 2005-04-07 | Allergan, Inc. | Methods and compositions for the oral administration of prodrugs of proton pump inhibitors |
| US20070292498A1 (en) * | 2003-11-05 | 2007-12-20 | Warren Hall | Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers |
| WO2005082338A2 (en) * | 2004-02-18 | 2005-09-09 | Allergan, Inc. | Prodrugs for the intravenous administration of proton pump inhibitors |
| AU2005216862A1 (en) * | 2004-02-18 | 2005-09-09 | Allergan, Inc. | Compositions comprising prodrugs of proton pump inhibitors |
| WO2005117870A2 (en) * | 2004-04-16 | 2005-12-15 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and prokinetic agent |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US20050267157A1 (en) * | 2004-05-28 | 2005-12-01 | David White | Magnesium-S-omeprazole |
| US20050267159A1 (en) * | 2004-05-28 | 2005-12-01 | Aaipharma, Inc. | Magnesium complexes of S-omeprazole |
| AU2005264864B2 (en) | 2004-06-16 | 2011-08-11 | Takeda Pharmaceutical Company Limited | Multiple PPI dosage form |
| NZ551970A (en) * | 2004-06-24 | 2010-01-29 | Astrazeneca Ab | New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt |
| ES2246149B1 (es) * | 2004-07-02 | 2007-06-01 | Esteve Quimica, S.A. | Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion. |
| US20060024362A1 (en) * | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
| US20060160783A1 (en) * | 2004-12-30 | 2006-07-20 | Transform Pharmaceuticals, Inc. | Novel omeprazole forms and related methods |
| ES2259269B1 (es) | 2005-03-03 | 2007-11-01 | Esteve Quimica, S.A. | Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos. |
| US20060210637A1 (en) * | 2005-03-17 | 2006-09-21 | Qpharma, Llc | Stable tablet dosage forms of proton pump inhibitors |
| WO2006120520A1 (en) * | 2005-05-06 | 2006-11-16 | Glenmark Pharmaceuticals Limited | Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same |
| WO2006134605A1 (en) | 2005-06-15 | 2006-12-21 | Hetero Drugs Limited | Amorphous esomeprazole hydrate |
| EP1904064A4 (en) * | 2005-07-07 | 2009-12-02 | Reddys Lab Ltd Dr | OMEPRAZOLE OF FORM B |
| KR100641534B1 (ko) | 2005-07-28 | 2006-11-01 | 한미약품 주식회사 | 에스오메프라졸 및 그의 염의 제조방법 |
| US20070026071A1 (en) * | 2005-07-28 | 2007-02-01 | Qpharma, Llc | Magnesium salt proton pump inhibitor dosage forms |
| WO2007031845A2 (en) * | 2005-09-14 | 2007-03-22 | Glenmark Pharmaceuticals Limited | Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation |
| BRPI0617987A2 (pt) * | 2005-10-06 | 2011-08-16 | Auspex Pharmaceuticals Inc | composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico |
| US7576219B2 (en) | 2005-10-26 | 2009-08-18 | Hanmi Pharm. Co., Ltd | Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same |
| AU2006306906B2 (en) * | 2005-10-26 | 2010-02-04 | Hanmi Science Co., Ltd. | S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same |
| EP1801110A1 (en) | 2005-12-22 | 2007-06-27 | KRKA, tovarna zdravil, d.d., Novo mesto | Esomeprazole arginine salt |
| US7553857B2 (en) * | 2005-12-23 | 2009-06-30 | Lek Pharmaceuticals D.D. | S-omeprazole magnesium |
| CN100384839C (zh) * | 2006-02-17 | 2008-04-30 | 中国科学院上海有机化学研究所 | [(取代的吡啶基)甲基]亚磺酰基-1h-苯并咪唑类化合物及其对映体的锌盐的制备方法 |
| US7579476B2 (en) * | 2006-02-24 | 2009-08-25 | Praktikatalyst Pharma, Llc | Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals |
| US8063074B2 (en) | 2006-05-04 | 2011-11-22 | Dr. Reddy's Laboratories Limited | Polymorphic forms of esomeprazole sodium |
| US20100286208A1 (en) * | 2006-06-21 | 2010-11-11 | Bobba Venkata Siva Kumar | Novel polymorph of esomeprazole potassium and process for its preparation |
| GB2444593B (en) | 2006-10-05 | 2010-06-09 | Santarus Inc | Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations |
| WO2008057802A2 (en) | 2006-10-27 | 2008-05-15 | The Curators Of The University Of Missouri | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same |
| EP1947099A1 (en) * | 2007-01-18 | 2008-07-23 | LEK Pharmaceuticals D.D. | Process for solvent removal from omeprazole salts |
| WO2008092939A2 (en) | 2007-01-31 | 2008-08-07 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation |
| AU2008217603C1 (en) * | 2007-02-21 | 2013-08-15 | Cipla Limited | Process for the preparation of esomeprazole magnesium dihydrate |
| KR101303813B1 (ko) * | 2007-04-16 | 2013-09-04 | 에스케이케미칼주식회사 | 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법 |
| EP2000468A1 (en) | 2007-05-09 | 2008-12-10 | Dr. Reddy's Laboratories Ltd. | Esomeprazole salts and processes for preparation thereof |
| ATE534643T1 (de) * | 2007-06-07 | 2011-12-15 | Aurobindo Pharma Ltd | Verbessertes verfahren zur herstellung eines optisch aktiven protonenpumpenhemmers |
| FR2920428B1 (fr) * | 2007-08-29 | 2012-06-15 | Univ Rouen | Procede de dedoublement de sels de l'omeprazole |
| US8106210B2 (en) * | 2007-10-08 | 2012-01-31 | Hetero Drugs Limited | Polymorphs of esomeprazole salts |
| BRPI0818286A2 (pt) | 2007-10-12 | 2020-08-11 | Takeda Pharmaceuticals North America, Inc. | métodos de tratamento de distúrbios gastrointestinais independente da ingestão de alimento. |
| WO2009074997A2 (en) * | 2007-12-10 | 2009-06-18 | Lee Pharma Ltd. | A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate |
| EP2240496A4 (en) * | 2008-02-01 | 2011-05-11 | Reddys Lab Ltd Dr | PREPARATION OF MAGNESIUM OF ESOMEPRAZOLE AND ITS HYDRATES |
| US20090280173A1 (en) * | 2008-05-09 | 2009-11-12 | Ishwar Chauhan | Multilayer Omeprazole Tablets |
| US20090280175A1 (en) * | 2008-05-09 | 2009-11-12 | Ishwar Chauhan | Multilayer Proton Pump Inhibitor Tablets |
| EP2143722A1 (en) | 2008-07-09 | 2010-01-13 | Lek Pharmaceuticals D.D. | Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium |
| EP2147918A1 (en) | 2008-07-21 | 2010-01-27 | LEK Pharmaceuticals D.D. | Process for the preparation of S-omeprazole magnesium in a stable form |
| CN102209529A (zh) | 2008-09-09 | 2011-10-05 | 阿斯利康(瑞典)有限公司 | 将药物组合物递送至有需要的患者的方法 |
| CN101391993B (zh) * | 2008-10-28 | 2012-07-04 | 安徽美诺华药物化学有限公司 | 通过与(s)-(-)-1,1'-联萘-2,2'-二酚形成包合配合物制备s-奥美拉唑及其盐的方法 |
| WO2010097583A1 (en) | 2009-02-24 | 2010-09-02 | Cipla Limited | Esomeprazole potassium polymorph and its preparation |
| US20100267959A1 (en) * | 2009-04-15 | 2010-10-21 | Glenmark Generics Limited | Process for the preparation of esomeprazole magnesium dihydrate |
| WO2010122583A2 (en) | 2009-04-24 | 2010-10-28 | Rubicon Research Private Limited | Oral pharmaceutical compositions of acid labile substances |
| US20130030186A1 (en) * | 2009-06-02 | 2013-01-31 | Sun Pharmaceutical Industries Limited | Process for preparing sulphoxide compounds |
| AU2010263304A1 (en) | 2009-06-25 | 2012-02-02 | Astrazeneca Ab | Method for treating a patient at risk for developing an NSAID-associated ulcer |
| WO2010151697A1 (en) * | 2009-06-25 | 2010-12-29 | Pozen Inc. | Method for treating a patient in need of aspirin therapy |
| WO2011012957A1 (en) * | 2009-07-29 | 2011-02-03 | Orchid Chemicals & Pharmaceuticals Ltd | An improved process for the preparation of esomeprazole magnesium dihydrate |
| US8748619B2 (en) | 2009-11-12 | 2014-06-10 | Hetero Research Foundation | Process for the resolution of omeprazole |
| US8895271B2 (en) | 2009-12-08 | 2014-11-25 | Codexis, Inc. | Synthesis of prazole compounds |
| US20110207779A1 (en) * | 2010-02-25 | 2011-08-25 | Glenmark Generics Ltd | Process for the preparation of esomeprazole magnesium |
| FR2959509B1 (fr) | 2010-05-03 | 2012-07-13 | Prod Chim Auxiliaires Et De Synthese | Phase precurseur et son utilisation pour preparer le sel de magnesium tetrahydrate d'un enantiomere d'omeprazole |
| CN102241668B (zh) * | 2010-05-11 | 2015-11-25 | 中国科学院成都有机化学有限公司 | S-奥美拉唑盐 |
| DK2649187T3 (da) | 2010-12-08 | 2018-01-29 | Codexis Inc | Biokatalysatorer og fremgangsmåder til syntesen af armodafinil |
| CN102757421A (zh) * | 2011-04-29 | 2012-10-31 | 江苏正大天晴药业股份有限公司 | 埃索美拉唑的纯化方法 |
| CN102911158B (zh) * | 2011-07-31 | 2015-07-22 | 连云港润众制药有限公司 | 埃索美拉唑镁的晶型 |
| CN102936238B (zh) * | 2011-11-25 | 2015-02-18 | 成都自豪药业有限公司 | S-奥美拉唑镁盐的晶型及其制备方法 |
| WO2013088272A1 (en) * | 2011-12-14 | 2013-06-20 | Wockhardt Limited | Pharmaceutical composition comprising esomeprazole magnesium dihydrate |
| WO2013101897A2 (en) | 2011-12-28 | 2013-07-04 | Pozen Inc. | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
| CN102584792B (zh) * | 2012-01-06 | 2014-06-11 | 南京优科生物医药研究有限公司 | 制备高纯度的埃索美拉唑盐的方法 |
| CN102993184A (zh) * | 2013-01-08 | 2013-03-27 | 湖南方盛制药股份有限公司 | 一种埃索美拉唑及其镁盐三水合物的制备方法 |
| CN104250243B (zh) * | 2013-06-27 | 2016-12-28 | 四川国为制药有限公司 | 一种埃索美拉唑镁二水合物a晶型的制备方法 |
| CN103570686B (zh) * | 2013-10-14 | 2015-04-01 | 哈药集团技术中心 | 一种埃索美拉唑钠的合成及精制工艺 |
| CN104725357A (zh) * | 2013-12-24 | 2015-06-24 | 苏州联友制药技术有限公司 | 一种埃索美拉唑镁二水合物晶型b的制备方法 |
| FR3018812A1 (fr) * | 2014-03-21 | 2015-09-25 | Minakem | Nouvelle phase intermediaire de la forme a du sel de magnesium dihydrate d'un enantiomere de l'omeprazole |
| CN104447699A (zh) * | 2014-12-10 | 2015-03-25 | 哈药集团技术中心 | 一种埃索美拉唑镁三水合物的制备方法 |
| CN105111188B (zh) * | 2015-08-19 | 2018-01-19 | 扬子江药业集团有限公司 | 一种埃索美拉唑镁三水合物晶型的制备方法 |
| US10736855B2 (en) | 2016-02-25 | 2020-08-11 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
| CN106397402B (zh) * | 2016-08-30 | 2019-05-03 | 山东罗欣药业集团股份有限公司 | 一种埃索美拉唑镁晶型化合物及其制备方法 |
| KR102006777B1 (ko) | 2018-01-29 | 2019-10-08 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제 |
| KR102080023B1 (ko) | 2018-01-29 | 2020-02-21 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물 |
| JP7506892B2 (ja) * | 2018-08-21 | 2024-06-27 | 東和薬品株式会社 | 化合物の特定形状の結晶及びその製造方法 |
| CN112839635A (zh) | 2018-08-23 | 2021-05-25 | 株式会社钟根堂 | 包含埃索美拉唑及碳酸氢钠的具有优秀的释放特性的药剂学制剂 |
| KR102432084B1 (ko) | 2021-11-16 | 2022-08-12 | 알리코제약(주) | S-오메프라졸을 함유하는 안정성이 개선되고 소형화된 정제 |
| EP4598528A1 (en) | 2022-10-04 | 2025-08-13 | Arsenil Zabirnyk | Inhibition of aortic valve calcification |
| CN119320380B (zh) * | 2024-10-14 | 2025-11-25 | 山东益康药业股份有限公司 | 奥美拉唑与2,6-二羟基苯甲酸的共晶物及其用途 |
| CN119320381A (zh) * | 2024-10-14 | 2025-01-17 | 山东益康药业股份有限公司 | 奥美拉唑与3,5-二硝基苯甲酸的共晶物及其用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| SE8301182D0 (sv) | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
| US5244891A (en) * | 1985-08-05 | 1993-09-14 | Bristol-Myers Squibb Company | Injectable compositions of cefepime dihydrochloride hydrate |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| US5204118A (en) | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
| SE9002043D0 (sv) * | 1990-06-07 | 1990-06-07 | Astra Ab | Improved method for synthesis |
| DE4035455A1 (de) * | 1990-11-08 | 1992-05-14 | Byk Gulden Lomberg Chem Fab | Enantiomerentrennung |
| US5360582A (en) | 1991-07-15 | 1994-11-01 | Minnesota Mining And Manufacturing Company | Nonlinear optical materials containing polar disulfone-functionalized molecules |
| US5877192A (en) | 1993-05-28 | 1999-03-02 | Astra Aktiebolag | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
| SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| SE9302396D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
| SE9302395D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
| FR2719045B1 (fr) * | 1994-04-20 | 1996-05-31 | Rhone Poulenc Chimie | Procédé de préparation d'acide L-aspartique à partir d'aspartate d'ammonium. |
| FR2722191B1 (fr) * | 1994-07-08 | 1996-08-23 | Rhone Poulenc Rorer Sa | Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle |
| ES2100142T3 (es) | 1994-07-08 | 2002-03-01 | Astrazeneca Ab | Forma de dosificacion en tabletas i constituida por unidades multiples. |
| SE504459C2 (sv) | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
| DK0792879T3 (da) * | 1994-11-14 | 2001-03-26 | Daiichi Seiyaku Co | Fremgangsmåde til fremstilling af 3-[2-[4-(3-chlor-2-methylphenyl)-1-piperzinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl) |
| GB9423970D0 (en) * | 1994-11-28 | 1995-01-11 | Astra Ab | Oxidation |
| SE9500422D0 (sv) | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
| CN1042423C (zh) | 1995-05-25 | 1999-03-10 | 常州市第四制药厂 | 奥美拉唑盐水合物及其制备方法 |
| SE9600070D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| SE9600071D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
| SE9600072D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients II |
| US6747155B2 (en) | 1997-05-30 | 2004-06-08 | Astrazeneca Ab | Process |
| SE510650C2 (sv) * | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
| AR057181A1 (es) | 2005-11-30 | 2007-11-21 | Astra Ab | Nueva forma de dosificacion de combinacion |
-
1997
- 1997-05-30 SE SE9702065A patent/SE510650C2/sv not_active IP Right Cessation
-
1998
- 1998-05-05 US US09/077,719 patent/US6369085B1/en not_active Expired - Lifetime
- 1998-05-15 HR HR980263A patent/HRP980263B1/xx not_active IP Right Cessation
- 1998-05-18 AR ARP980102299A patent/AR012717A1/es active IP Right Grant
- 1998-05-18 ZA ZA984179A patent/ZA984179B/xx unknown
- 1998-05-18 DZ DZ980105A patent/DZ2495A1/xx active
- 1998-05-18 TW TW087107675A patent/TW538040B/zh not_active IP Right Cessation
- 1998-05-21 MA MA25085A patent/MA26500A1/fr unknown
- 1998-05-25 EP EP98926005.4A patent/EP0984957B3/en not_active Expired - Lifetime
- 1998-05-25 ME MEP-249/08A patent/MEP24908A/xx unknown
- 1998-05-25 JP JP50057899A patent/JP4002303B2/ja not_active Expired - Lifetime
- 1998-05-25 CN CNB98805521XA patent/CN1161351C/zh not_active Expired - Lifetime
- 1998-05-25 UA UA99116288A patent/UA60334C2/uk unknown
- 1998-05-25 CZ CZ20041090A patent/CZ297585B6/cs not_active IP Right Cessation
- 1998-05-25 DE DE69829511T patent/DE69829511T2/de not_active Expired - Lifetime
- 1998-05-25 KR KR10-2005-7006896A patent/KR100527804B1/ko not_active Expired - Lifetime
- 1998-05-25 AU AU77935/98A patent/AU722839B2/en not_active Expired
- 1998-05-25 PT PT98926005T patent/PT984957E/pt unknown
- 1998-05-25 DK DK02019642T patent/DK1273581T3/da active
- 1998-05-25 RS RSP-2007/0459A patent/RS50067B/sr unknown
- 1998-05-25 EP EP02019642A patent/EP1273581B1/en not_active Expired - Lifetime
- 1998-05-25 ES ES02019642T patent/ES2236407T3/es not_active Expired - Lifetime
- 1998-05-25 ES ES98926005.4T patent/ES2195345T7/es active Active
- 1998-05-25 AT AT98926005T patent/ATE239011T1/de active
- 1998-05-25 SK SK1625-99A patent/SK284837B6/sk not_active IP Right Cessation
- 1998-05-25 SI SI9830761T patent/SI1273581T1/xx unknown
- 1998-05-25 ME MEP-2008-249A patent/ME00198B/me unknown
- 1998-05-25 KR KR1019997011106A patent/KR100540720B1/ko not_active Expired - Lifetime
- 1998-05-25 ID IDW991449A patent/ID29306A/id unknown
- 1998-05-25 NZ NZ500991A patent/NZ500991A/en not_active IP Right Cessation
- 1998-05-25 SK SK76-2005A patent/SK285137B6/sk not_active IP Right Cessation
- 1998-05-25 PT PT02019642T patent/PT1273581E/pt unknown
- 1998-05-25 EE EEP199900550A patent/EE03875B1/xx active Protection Beyond IP Right Term
- 1998-05-25 PL PL98337180A patent/PL193546B1/pl unknown
- 1998-05-25 SI SI9830424T patent/SI0984957T1/xx unknown
- 1998-05-25 HU HU0001849A patent/HU225987B1/hu active Protection Beyond IP Right Term
- 1998-05-25 BR BR9809509-9A patent/BR9809509A/pt not_active Application Discontinuation
- 1998-05-25 RU RU99128072/04A patent/RU2184115C2/ru active Protection Beyond IP Right Term
- 1998-05-25 IL IL13294798A patent/IL132947A0/xx not_active IP Right Cessation
- 1998-05-25 CA CA002521391A patent/CA2521391C/en not_active Expired - Lifetime
- 1998-05-25 DE DE69814069.9T patent/DE69814069T3/de not_active Expired - Lifetime
- 1998-05-25 CA CA002290963A patent/CA2290963C/en not_active Expired - Lifetime
- 1998-05-25 WO PCT/SE1998/000974 patent/WO1998054171A1/en not_active Ceased
- 1998-05-25 TR TR1999/02934T patent/TR199902934T2/xx unknown
- 1998-05-25 ME MEP-180/08A patent/MEP18008A/xx unknown
- 1998-05-25 AT AT02019642T patent/ATE291574T1/de active
- 1998-05-25 RS YUP-609/99A patent/RS50005B/sr unknown
- 1998-05-25 DK DK98926005T patent/DK0984957T3/da active
- 1998-05-27 EG EG58098A patent/EG24291A/xx active
- 1998-05-29 TN TNTNSN98074A patent/TNSN98074A1/fr unknown
- 1998-05-29 MY MYPI98002399A patent/MY120745A/en unknown
- 1998-05-29 MY MYPI20032997A patent/MY127793A/en unknown
- 1998-07-12 SA SA98190280A patent/SA98190280B1/ar unknown
- 1998-07-12 SA SA5260296A patent/SA05260296B1/ar unknown
-
1999
- 1999-11-25 IS IS5272A patent/IS2142B/is unknown
- 1999-11-29 NO NO19995852A patent/NO317518B1/no not_active IP Right Cessation
-
2002
- 2002-02-14 US US10/076,711 patent/US6677455B2/en not_active Expired - Lifetime
-
2003
- 2003-09-25 US US10/672,936 patent/US7411070B2/en not_active Expired - Fee Related
-
2006
- 2006-03-22 IS IS8368A patent/IS2774B/is unknown
-
2007
- 2007-02-20 AR ARP070100714A patent/AR059589A2/es active IP Right Grant
- 2007-03-16 JP JP2007068061A patent/JP2007161734A/ja active Pending
- 2007-09-11 US US11/853,323 patent/US7745466B2/en not_active Expired - Fee Related
-
2010
- 2010-05-21 US US12/784,881 patent/US8076361B2/en not_active Expired - Fee Related
-
2011
- 2011-06-07 NO NO2011010C patent/NO2011010I1/no not_active Application Discontinuation
- 2011-09-19 LU LU91871C patent/LU91871I2/fr unknown
- 2011-11-17 US US13/298,373 patent/US8466175B2/en not_active Expired - Fee Related
-
2012
- 2012-03-26 DE DE201212000017 patent/DE122012000017I1/de active Pending
- 2012-06-05 NO NO2012011C patent/NO2012011I1/no unknown
- 2012-06-06 LU LU92017C patent/LU92017I2/fr unknown
- 2012-11-05 CY CY2012029C patent/CY2012029I1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE510650C2 (sv) | Ny förening | |
| NO319719B1 (no) | Kaliumsalt av (S)-omeprazol | |
| US6747155B2 (en) | Process | |
| CZ296154B6 (cs) | Trihydrát horecnaté soli S-omeprazolu, zpusob jeho prípravy a farmaceutický prostredek s jeho obsahem | |
| MXPA99010945A (en) | Novel form of s | |
| HK1025962B (en) | Novel form of s-omeprazole | |
| HK1051681B (en) | New process for the preparation of the trihydrate of the magnesium salt of s-omeprazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |